Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 11/20 | 0.79 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.79 |
| ▸ | SRC | P12931 | 7/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.79 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | HCK | P08631 | 1/20 | 0.65 |
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | JAK3 | P52333 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | BLK | P51451 | 1/20 | 0.62 |
| ▸ | BMX | P51813 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22807504 | 0.93 | MAP3K7 (0.79) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL22807459 | 0.91 | SRC (0.80) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL22807515 | 0.88 | SRC (0.84) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL29549252 | 0.88 | SRC (0.84) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL31684786 | 0.88 | SRC (1.00) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL22828520 | 0.88 | SRC (1.00) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL28981021 | 0.87 | SRC (0.67) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL22807541 | 0.86 | SRC (0.80) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL28980965 | 0.85 | MAP3K7 (0.81) | MAP3K7MAP2K1SRCMAPK1FGFR1 | |
| SCHEMBL31684777 | 0.85 | MAP3K7 (0.80) | MAP3K7MAP2K1SRCMAPK1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20220267294-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-08-25 | — | — | US | disclosed |
| EP-3986411-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020257385-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257385-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | SRC, CTTN, LCK | MAP3K7 42/4885MAP2K1 1114/4885SRC 1/4885 |
| US-20220267294-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | SRC, CTTN, LCK | MAP3K7 42/4885MAP2K1 1114/4885SRC 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.